Antibody Drugs: Technologies and Global Markets

Report Code: BIO016M

Publish Date: Sep 2024

Publisher: BCC Publishing

Category: Cell Biology

Download Report Overview

Single User License: $5500

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.

Report Includes

  • 76 data tables and 55 additional tables
  • An updated review of the global market for antibody drugs
  • Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
  • Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
  • Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
  • An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
  • Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
  • Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
  • Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.

Report Scope

This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).

BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.

Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.

The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America—the U.S., Canada and Mexico; Europe—Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific—China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.

Report Synopsis

Report Metrics Details
Base year considered 2023
Forecast period considered 2024-2029
Base year market size $218.6 billion
Market size forecast $412.1 billion
Growth rate CAGR of 11.2% for the forecast period of 2024-2029
Units considered $ Millions
Segments covered Antibody Type, Manufacturing Process Type, Application, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Countries covered U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, China, Japan, India, South Korea, and Australia
Key Market Drivers
  • Growing incidence of cancer and autoimmune diseases.
  • Increasing product approvals.
  • Rising collaborations and partnerships for antibody drug development.
Companies studied
ABBVIE INC.AMGEN INC.
ASTRAZENECA BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.JOHNSON & JOHNSON SERVICES INC.
LILLYMERCK KGAA
NOVARTIS AGPFIZER INC.
REGENERON PHARMACEUTICALS INC.SANOFI
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The antibody drugs market is projected to grow from $218.6 billion in 2023 to $412.1 billion in 2029 at a compound annual growth rate (CAGR) of 11.2% during the forecast period.
The increasing cancer and autoimmune diseases incidence and growing product approvals are driving the market growth.
The market is segmented by antibody type, manufacturing process, application, and region.
The human antibodies segment will dominate the market by the end of 2029.
North America has the highest market share.
F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Antibody Drugs: Technologies and Global Markets156Free
Chapter- 1: Executive Summary4Free
Chapter- 2: Market Overview8Free
Chapter- 3: Market Dynamics6Free
Chapter- 4: Regulatory Aspects4Free
Chapter- 5: Emerging Technologies and Developments 3Free
Chapter- 6: Market Segmentation Analysis64Free
Chapter- 7: Competitive Intelligence4Free
Chapter- 8: New Developments and Clinical Trial Activities 9Free
Chapter- 9: Sustainability: An ESG Perspective in the Antibody Drugs Market6Free
Chapter- 10: Appendix48Free
Published - Nov-2021| Analyst - BCC Publishing| Code - BIO016L

Report Highlights

The global market for antibody drugs should grow from $126.7 billion in 2021 to $208.6 billion by 2026 with a compound annual growth rate (CAGR) of 10.5% for the period of 2021-2026. 

Report Includes

  • 30 data tables and 29 additional tables
  • An overview of the global market for antibody drugs and related applications and technologies
  • Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for antibody drugs by type, application, and region
  • Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
  • Details of antibody functions, its comparison with antigen, and description of monoclonal antibodies, their history, advantages and disadvantages, types, manufacturing technologies and applications
  • Coverage of new approvals, recalls, safety alerts and clinical trials of monoclonal antibodies and information on technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
  • Information about major technologies for the formulation of antibody drugs and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Comprehensive company profiles of the leading players including F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., and Merck & Co.
Published - Oct-2017| Analyst - Shalini Shahani Dewan| Code - BIO016K

Report Highlights

The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022. 

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
Published - Jan-2015| Analyst - Shalini Shahani Dewan| Code - BIO016J

Report Highlights

The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
Published - Feb-2012| Analyst - Esther Bosklopper| Code - BIO016H

Report Highlights

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Published - Jan-2008| Analyst - Kim Lawson| Code - BIO016G

Report Highlights

This Report:

  • The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%.
  • In 2007, the U.S. Food and Drug Administration approved 21 therapeutic monoclonal antibodies for therapeutic use under a drug approval review.
  • Monoclonal antibodies are a significant part of effective medical treatment and of financial deals within the biotechnology and pharmaceutical sectors of the economy.
Published - Aug-2005| Analyst - Lynn Gray| Code - BIO016F

Report Highlights

  • The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
  • Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
  • The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
  • The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.
Published - Oct-2002| Analyst - Lynn Gray| Code - BIO016E

Report Highlights

  • As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
  • The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.

Published - Feb-2000| Analyst - Lynn Gray| Code - BIO016D

Report Highlights

  • Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
  • The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
  • The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.

Related Reports

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Antibody-Drug Conjugates: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - PHM161C

The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

Global Recombinant Proteins Market

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO254A

The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.

PEGylated Proteins Market

Published - May 2024 | Publisher - BCC Publishing | Code - BIO253A

The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.

Recent Reports

RNA Sequencing: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO147B

The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.1% during the forecast period of 2024 to 2029.

Antibody Drugs: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO016M

The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.

European Life Science Tools and Reagents Market

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO262A

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 3.4% from 2024 through 2029.

Global Multiomics Market

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO260A

The global market for multiomics is expected to grow from $2.7 billion in 2024 and is projected to reach $5.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.

Drug Discovery Technologies

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO020H

The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.

Top Trending Reports

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

Artificial Intelligence (AI) in Life Sciences Market

Published - Aug 2024 | Publisher - BCC Publishing | Code - BIO255A

The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.

Drug Discovery Technologies

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO020H

The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.

Synthetic Biology: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - BIO066H

The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.

Electric Vehicles and Fuel Cell Vehicles: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - FCB040F

The global market for electric vehicles and fuel cell vehicles was valued at $655.9 billion in 2023. The market is expected to grow from $758.0 billion in 2024 to $1.8 trillion by 2029, at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Antibody Drugs: Technologies and Global Markets
Sample Report